AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🌍 Showing

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Condition

Country

City (shown first)

30 recruiting trials

for Metastatic Lung Cancer

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644Phase 31 site📍 Jinan Qilu Pharmaceutical Co., Ltd. · Tests: QL2107, Pemetrexed, Carboplatin, Keytruda® Safety and Feasibility of Intraoperative Visualization With Cytalux in Children NCT06235125Phase 11 site📍 Chicago Ann & Robert H Lurie Children's Hospital of Chicago · Tests: Cytalux ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site📍 Shanghai Fudan University · Tests: ORIENT-31 regimen, SBRT A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site📍 Hangzhou Betta Pharmaceuticals Co., Ltd. · Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8… A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites📍 Birmingham📍 Duarte📍 Boston Taiho Oncology, Inc. · Tests: TAS6417, CYP Cocktail, Transporter Cocktail Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients NCT06481813NA4 sites📍 Angers📍 Nantes📍 Rennes Nantes University Hospital · Tests: Blood Sampling (2*8mL Tubes), PBMC Sampling (1*8mL Tubes), Paxgene Sampling, Extended biopsies of tumor lesions A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer NCT07017829Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride A Phase Ib Study of GC101 in NSCLC NCT06473961Phase 11 site📍 Shanghai Shanghai Juncell Therapeutics · Tests: Autologous Tumor Infiltrating Lymphocytes A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole A Study of Armored CAR T Cells in People With Cancer NCT07783477Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: DLL3-SAVVYZ-IL18 CAR T cell A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites📍 Hefei📍 Harbin📍 Wuhan Abbisko Therapeutics Co, Ltd · Tests: ABSK043 in combination with Firmonertinib Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer NCT05384873NA1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: Immunonutrition, Control dietary intervention Comprehensive Outcomes for After Cancer Health NCT05349227NA7 sites📍 Gainesville📍 Boston📍 Omaha Pack Health · Tests: Digital Health Coaching Program, Fitbit Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 NCT07264569Phase 1, Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: BioTTT001 injection AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113Phase 139 sites📍 Duarte📍 Los Angeles📍 Atlanta Amgen · Tests: AMG 410, Pembrolizumab, Panitumumab A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites📍 Bakersfield📍 Beverly Hills📍 Stamford Merck Sharp & Dohme LLC · Tests: Calderasib, Placebo, Pembrolizumab GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations NCT06430437Phase 31 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531Phase 31 site📍 Shanghai Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Tests: ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Vebreltinib, Furmonertinib 80mg A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation NCT07809256Phase 31 site📍 Saint Petersburg EuroCityClinic LLC · Tests: lenvatinib pembrolizumab A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY). NCT05354596NA6 sites📍 Aalborg📍 Aarhus📍 Copenhagen Copenhagen University Hospital, Rigshospitalet · Tests: STRICT LUNG, STAR LUNG Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial NCT06563388Phase 31 site📍 Buffalo Roswell Park Cancer Institute · Tests: Stereotactic Ablative Radiotherapy, Best Practice Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor

🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy